['chronic hepatitis c']
['danoprevir', 'ritonavir', 'peginterferon alfa-2a', 'rbv']

        Inclusion Criteria:

          -  Willing and able to provide written informed consent

          -  Chronic HCV infection (≥ 6 months)

          -  Serum HCV RNA of ≥ 1 × 104 IU/mL are documented

          -  Hepatitis C virus GT1

          -  Never received prior-treatment for HCV with interferon, RBV, or other direct-acting or
             host-targeting antivirals for HCV

          -  Non-cirrhosis patients: Non-cirrhosis is defined (1)Fibroscan defined as: ˂ 14.6 kPa
             during screening period, or liver biopsy determined 1 year before recruiting (Metavir
             score ˂ 3);(2) during screening period 9.6<Fibroscan indicator ≤12.9, liver biopsy
             need to confirm non-cirrhosis.

          -  Others as specified in the detailed protocol

        Exclusion Criteria:

          -  Patients with Fibroscan detection value > 12.9 kPa, or histologic examination for
             liver cirrhosis patients

          -  Presence or history of non-hepatitis C chronic liver disease (e.g. HH, AIH, Wilson's
             disease, α1 antitrypsin deficiency, drug- or toxin-induced liver disease)

          -  History of liver cell cancer, or suspected hepatocellular carcinoma (HCC) patients
             before or during screening , or imaging studies found suspicious nodules, or AFP > 50
             ng/mL

          -  Positive hepatitis A antibody，positive hepatitis B surface antigen，HIV antibody

          -  Presence or history of nervous system diseases and/or mental illness, inability to
             control oneself or express oneself.

          -  Patients with obvious cardiovascular dysfunction

          -  Pregnant or nursing female, nor unwilling to take reliable contraception

          -  Others as specified in the detailed protocol
      